Serum LDH (≥1400 U/L), age ≥ 18 months, BP ≥ 7 and genome subgroup GG-P2s will be good candidates to be included in the next version of the risk score to identify particularly high risk NB populations in MYCN-non-amplified stage 4 patients. This evidence concerns the gene MYCN and neuroblastoma.